Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo has acquired the exclusive US store brand rights to sell and distribute dextromehtorphan polistirex extended release suspension cough suppressant (DELSYM), the generic version of Reckitt Benckiser's Delsym from Tris Pharma.
Subscribe to our email newsletter
Tris Pharma has a first to file ANDA application for the generic that can entitle it to 180 days of generic exclusivity upon approval. Tris Pharma and Reckitt Benckiser are currently engaged in Paragraph IV/Hatch-Waxman litigation over the Tris ANDA filing.
Under the agreement Perrigo and Tris Pharma are expected to share profits, and Perrigo will pay Tris Pharma certain milestone payments.
Joseph Papa, chairman and CEO of Perrigo, said: “This is another example of Perrigo’s focus on introducing new products which will make quality healthcare more affordable to American consumers.”
Ketan Mehta, CEO of Tris Pharma, said: “Tris Pharma was able to file this first ever generic of a sustained release liquid product via Tris Pharma’s proprietary OralXR+ technology. We are pleased to work with Perrigo, the clear OTC store with this important product.”